European Medicines Agency

08 July 2005
EMEA/CHMP/207020/2005

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE
JUNE 2005 PLENARY MEETING
MONTHLY REPORT

The Committee for Medicinal Products for Human Use (CHMP) held its June plenary meeting from 20 - 23 June 2005.

Centralised procedure

Initial applications for marketing authorisation

The CHMP adopted positive opinions on three initial marketing authorisation applications for:

- **Tarceva** (erlotinib), from Roche Registration Ltd, for the treatment of locally advanced or metastatic non-small cell lung cancer. The EMEA review began on 20 September 2004 with an active review time of 193 days.
- **Vasovist** (gadofosveset), from Schering AG, for diagnostic use in contrast enhanced magnetic resonance angiography for visualization of abdominal or limb vessels in patients with suspected or known vascular disease. The EMEA review began on 21 June 2004 with an active review time of 182 days.
- **Xyrem** (sodium oxybate), from UCB Pharma Ltd, for the treatment of cataplexy in patients with narcolepsy. Xyrem is the **twenty-first orphan medicinal product** to receive a positive opinion. The EMEA review began on 29 March 2004 with an active review time of 198 days.

Extensions of indication and other recommendations

The Committee also adopted positive opinions on extension of indication for medicinal products that are already authorised in the European Union (EU) for:

- **Humira** and **Trudexa** (adalimumab), Abbott Laboratories, to include treatment in combination with methotrexate of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.

  Further positive opinions were given to extend the indication to include the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. Humira was first authorised in the EU on 8 September 2003. Trudexa was first authorised in the EU on 1 September 2003.

The CHMP also recommended the approval of **Bondenza** (ibandronic acid), **Bonviva** (ibandronic acid) 150 mg film-coated tablets indicated for the treatment of osteoporosis. This higher strength is for once monthly administration compared to once daily previously authorised.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 84 16
E-mail: mail@emea.eu.int http://www.emea.eu.int

In addition, for **Infergen** (interferon alfacon-1) the CHMP recommended to replace the contra-indication in patients with severe psychiatric conditions by a warning and for **Refacto** (moroctocog alfa) the CHMP recommended deletion of one contra-indication.

Summaries of opinion for these medicinal products are available on the EMEA website: http://www.emea.eu.int. Further information will be included in the European Public Assessment Report (EPAR) once the European Commission has granted final approval.

Lists of Questions

The Committee adopted two Lists of Questions on initial applications (2 Part B) and one List of Questions on a "line extension" application (Part A) (in accordance with Annex II of Commission Regulation (EC) No. 1085/2003).

Detailed information on the centralised procedure

An overview of centralised procedures since 1995 is given in **Annex 1**. The European Commission has granted no marketing authorisations for medicinal products since the CHMP plenary meeting in May 2005. The post-authorisation centralised procedures finalised during this meeting are summarised in **Annex 2.**

Applications for marketing authorisation for orphan medicinal products

No Orphan medicinal products have been the subject of a centralised application for marketing authorisation since the May 2005 CHMP meeting.

Arbitration procedure

The CHMP concluded an arbitration procedure for two generic medicinal products containing **lanzoprazol** (Lonsopon and Lanzoprazole Hexal), with the recommendation to harmonise the summaries of product characteristics (SPCs) of these products. The procedure was initiated under Article 29(2) of the Community code on human medicines (Directive 2001/83/EC, as amended) because of differences in the indication and posology section between the SPCs of the reference product and the SPCs of the generic products.

The CHMP concluded the review of COX-2 inhibitors. A separate statement was issued and can be found: http://www.emea.eu.int/Cox2inhibitors.htm.

CHMP Working Parties

The CHMP was informed of the outcome of the discussions of the Scientific Advice Working Party (SAWP) meeting, which was held on 6 – 7 June 2005. For further details, please see **Annex 3**.

Documents prepared by the CHMP Working Parties adopted during the June 2005 CHMP meeting are listed in **Annex 4**.

Upcoming meetings following the June 2005 CHMP plenary meeting:

- The 13th meeting of the CHMP will be held at the EMEA on 25 – 28 July 2005.
- The next Invented Name Review Group meeting will be held at the EMEA on 25 July 2005.
- The next Mutual Recognition Facilitation Group Meeting will be held at the EMEA on 25 – 26 July 2005.

Organisational matters

The main topics addressed during the June 2005 CHMP related to:

- The adoption of the revised Composition of the Pharmacogenetics Working Party (PgWP).

- The adoption of nominations for the CHMP Scientific Advisory Group on Diabetes/Endocrinology (SAG-D/E).

- The adoption of the Mandate, Objectives and Rules of Procedure for the CHMP Pharmacovigilance Working Party. The adopted documents will be available on the EMEA website: http://www.emea.eu.int

- The adoption of the following Annex Guidelines on similar biological medicinal products containing biotechnology-derived proteins as active substance. These Annex Guidelines are released on the EMEA website: http://www.emea.eu.int (please see also **Annex 4**):

    - "Annex guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues-guidance on biosimilar medicinal products containing recombinant erythropoeitins"
    - "Annex guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues-guidance on biosimilar medicinal products containing recombinant granulocyte-colony stimulating factor"

EMEA implementation of the New EU Pharmaceutical Legislation

The fifth CHMP/EMEA Implementation Task Force (CEITAF) meeting took place on Monday 20 June 2005.

Documents on the following review implementation topics were adopted by the CHMP and will be transmitted to the European Commission:

- Pharmacovigilance Inspections
- Publication of withdrawal opinions

A follow-up discussion took place on the Pharmacovigilance risk management system evaluation/procedure.

Initial discussions took place on the following review implementation topics: Renewals in the Centralised procedure, Handling of 'consultations with target patient groups' in the Centralised procedure, Coordination between the Scientific Committees of the Agency, Actual marketing and cessation and Sunset Clause.

Mutual Recognition procedure

The CHMP noted the report from the Mutual Recognition Facilitation Group (MRFG) meeting held on 20 – 21 June 2005. For further details, please see **Annex 5**.

Noël Wathion
Head of Unit
Post-Authorisation Evaluation of Medicines for Human Use, Tel. (+44-20) 74 18 85 92
This CHMP Monthly Report and other documents are available on the Internet at the following address: http://www.emea.eu.int

EMEA CENTRALISED PROCEDURES

	1995 - 2004	2005	Overall Total
Scientific Advice	433	56	489
Follow-up to Scientific Advice	71	9	80
Protocol Assistance	59	23	82
Follow-up to Protocol Assistance	12	3	15

	1995-2004			2005			Overall Total
	Part A	Part B	Total	Part A	Part B	Total	
Applications submitted	153	303	456	3	15	18	474
Consultation for Medical Device[1]	0	1	1	0	1	1	2
Withdrawals	22	62	84	0	3	3	87
Positive opinions[2]	107	197	304	0	6	6	310[3]
Negative opinions[4]	2	5	7	0	0	0	7[5]
Marketing authorisations granted by the Commission	98	190	288	3	7	10	298[6]

	1995-2004			2005			Overall Total
	Part A	Part B	Total	Part A	Part B	Total	
Variations type I	863	1937	2800	79	199	278	3078
Positive opinions, variations type II	758	886	1644	129	109	238	1882
Negative opinions, variations type II	1	6	7	0	0	0	7
Extensions (Annex II applications)	53	63	116	5	4	9	125

[1] Consultation in accordance with Council Directive 93/42/EEC concerning medical devices as amended by Directive 2000/70/EC as regards medical devices incorporating stable derivatives of human blood or plasma and Directive 2001/104/EC.
[2] 20 positive opinion corresponding to 20 Orphan Medicinal Products
[3] 310 positive opinions corresponding to 241 substances
[4] In case of appeal, the opinion will not be counted twice
[5] 7 negative opinions corresponding to 6 substances (2 of these negative opinions correspond to 2 Orphan Medicinal Products)
[6] 298 marketing authorisations corresponding to 229 substances

OUTCOME OF THE JUNE 2005 CHMP MEETING IN RELATION TO CENTRALISED APPLICATIONS IN THE POST-AUTHORISATION PHASE

Opinions for Type II Variation applications	
Number of Opinions	**Outcome**
5 Extensions of indication	5 Positive opinions
22 SPC changes	22 Positive opinions
22 Quality changes	22 Positive opinions

Opinions for Annual Re-Assessment applications		
Name of Medicinal Product (INN)	**Outcome**	**Comments**
Trisenox (arsenic trioxide) Cell Therapeutics (UK) Ltd	Positive Opinion	The authorisation will remain under exceptional circumstances
Reyataz (atazanavir sulphate Bristol Myers Squibb Pharma EEIG	Positive Opinion	The authorisation will remain under exceptional circumstances

Opinions for Renewal applications		
Name of Medicinal Product (INN)	**Outcome**	**Comments**
Datscan (ioflupane) Nycomed Amersham	Positive Opinion	---
Herceptin (trastuzumab) Roche Registration Ltd	Positive Opinion	---
KOGENATE Bayer (octocog alfa) Bayer AG	Positive Opinion	---
Helixate NexGen (octocog alfa) Bayer AG	Positive Opinion	---
Myocet (doxorubicin) Elan Pharma International Ltd	Positive Opinion	---
NovoMix 30 (insulin aspart) Novo Nordisk	Positive Opinion	---

OUTCOME OF THE JUNE 2005 CHMP MEETING IN RELATION TO SCIENTIFIC ADVICE PROCEDURES

Substance	Intended indications(s)	Type of Request				Topic			
		New		Follow-up		Pharma ceutical	Pre-clinical	Clinical	Significant Benefit
		SA	PA	SA	PA				
Biological	Neutropenias			X				X	
Chemical	Insulin dependent diabetes			X			X	X	
Biological	Glioma.		X				X	X	X
Chemical	Cystic fibrosis		X				X	X	X
Chemical	Postmenopausal osteoporosis			X				X	
Chemical	Glioblastoma multiforme	X						X	
Chemical	Reversal of neuromuscular block	X				X	X	X	
Biological	Ovarian and peritoneal cancer			X			X	X	
Chemical	Gastro-intestinal tumours		X			X	X	X	
Chemical	Reduction of cardiovascular events	X						X	
Chemical	Non-small cell lung cancer			X				X	
Chemical	Fibromyalgia	X						X	
Chemical	Osteoarthritis	X						X	

Chemical	Gastro-entero-pancreatic neuroendocrine tumours		X				X	X	X

SA: Scientific Advice

PA: Protocol Assistance

The above-mentioned 5 Scientific Advice letters, 5 Follow-up Scientific Advice letters and 4 Protocol Assistance letters were adopted at the 20-23 June 2005 CHMP meeting.

The Committee accepted 11 Initial Scientific Advice Requests, 3 Initial Protocol Assistance Requests, 5 Follow-up Scientific Advice Requests and 2 Follow-up Protocol Assistance Requests.

.

DOCUMENTS PREPARED BY THE CHMP WORKING PARTIES ADOPTED DURING THE JUNE 2005 CHMP MEETING

WORKING PARTY ON BIOLOGICAL (BIOSIMILAR) MEDICINAL PRODUCTS

Reference number	Document	Status
CHMP/94526/2005	Annex guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues: guidance on biosimilar medicinal products containing recombinant erythropoietins	Adopted
CHMP/31329/2005	Annex guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues: guidance on biosimilar medicinal products containing recombinant granulocyte-colony stimulating factor	Adopted

EFFICACY WORKING PARTY

Reference number	Document	Status
CPMP/EWP/234/95/ rev.1	Guideline on the clinical investigation of anti-anginal medicinal products in stable angina pectoris	Released for 3 months consultation
CHMP/EWP/191583/ 2005	Questions and Answers document on the clinical development of fixed combinations of drugs belonging to different therapeutic classes in the field of cardiovascular treatment and prevention	Adopted
CHMP/EWP/4891/03	Guideline on clinical investigation of medicinal products for the treatment of Ankylosing Spondylitis	Released for 6 months consultation
CHMP/EWP/438/04	Guideline on clinical investigation of medicinal products for the treatment of Psoriatic Arthritis	Released for 6 months consultation
CHMP/EWP/195220 2005	Concept Paper on the development of a committee for medicinal products for human use (CHMP) Guideline on reporting the results of population pharmacokinetic analyses	Adopted
CPMP/EWP/422/04	Guideline on clinical investigation of medicinal products for the treatment of Juvenile Idiopathic Arthritis	Released for 6 months consultation

PAEDIATRIC WORKING PARTY

Reference number	Document	Status
EMEA/175192/2004/ rev.2	EMEA/PEG procedure for identifying paediatric needs	Adopted
CHMP/189220/2005	Assessment of the paediatric needs: pain	Released for 6 months consultation
CHMP/PEG/194810/2005	Reflection Paper: Formulations of choice for the paediatric population ▪ Note of Explanation to accompany the document (EMEA/196218/2005) ▪ Executive Summary of the document (CHMP/196986/2005)	Released for 6 months consultation

VACCINE WORKING PARTY

Reference number	Document	Status
	Core SPC on Pandemic Influenza	Adopted
CHMP/VWP/157496/ 2005	VWP report on pandemic influenza vaccines – recommendations to CHMP	Adopted

Report from the meeting held on 20 and 21 June 2005

General Issues

Joint MRFG/QRD Working Group on Patient information

The Joint MRFG/QRD Working Group on Patient information held its fourth meeting. The Working Group discussed the adaptation of the QRD product information templates for medicinal products for human use to be suitable for use in the Decentralised (DC) and Mutual Recognition (MR) procedures.

MRFG/CMD(h) Concept paper – Achieving harmonised patient information – Consultation procedure

The MRFG has endorsed the Concept paper – Achieving Harmonised Patient Information, developed by the Working Group on Patient information to assist Marketing Authorisation Holders with the new requirements of harmonised labelling and package leaflets for marketing authorisations granted in accordance with the DC or MR procedures, and has agreed to publish it for a 4 week consultation period with Interested Parties.

Any comments or proposals on the Concept paper should be sent by 21 July 2005 coordinated where possible by trade associations, to the MRFG secretariat (sonia.ribeiro@emea.eu.int).

Change in the EU-Presidency

The June 2005 MRFG meeting was the last one chaired by Truus Janse-de Hoog on behalf of the Luxembourg presidency. The United Kingdom will take over the presidency in July 2005. Shirley Norton will be the next MRFG chairperson and should be contacted in case of any questions regarding the MRP. See end for contact details.

Meeting schedule

The next MRFG meeting will be held on 25 and 26 July 2005.

Mutual Recognition Monitoring

The MRFG noted that **62** new mutual recognition procedures were finalised during the month of May 2005, as well as **303** type IA variations, **187** type IB variations and **131** type II variations. **1** arbitration according to Article 6(12) (of Commission Regulation (EC) No 1084/2003 has been referred to CHMP.

The status as of 31st May of procedures and for the whole year under mutual recognition is as follows:

Year	Procedures from New applications finalised	Procedures from New applications in process	Procedures from Type IA variations finalised	Procedures from Type IB variations finalised	Procedures from Type II variations finalised	Arbitrations referred to CHMP
2005	318	355	1500	695	454	2 Var.

122 new procedures (regarding **208** products) started in May 2005. The categories of these procedures are as follows:

2 new active substances of which **1** is classified as repeat use.

16 known active substances (already authorised in at least one member state), including **4** repeat use.

95 abridged applications including **34** multiple applications and **11** repeat use.

9 line extension applications including **6** repeat use.

The new procedures started related to **9** full dossiers, **89** generics, **7** bibliographic applications, **7** fixed combinations, **1** informed consent and **9** for different use, route or dose.

The procedures consisted of **120** chemical substances, **1** biological-other and **1** biological-vaccine[1].

113 of these procedures were prescription-only medicinal products in the reference Member State and **9** procedures was classified as a Non-prescription (including OTC) medicinal product[2].

1. As considered by RMS.
2. In this category products are classified as prescription-only or Non-prescription (OTC) products when the RMS has approved them accordingly, although the legal status is not part of the Mutual Recognition Procedure.

Number of countries involved in the new applications procedures started in May 2005

Reference Member State (number of products involved in the procedure)	Number of CMSs involved in the procedure
AT (1)	2
BE (2)	3
CZ (4)	7
DE (1)	1
DE (3)	4
DE (1)	16
DE (1)	1
DE (1)	11
DE (2)	5
DE (1)	6
DE (1)	2
DE (2)	2
DE (4)	7
DE (2)	7
DE (1)	1
DE (1)	4
DK (1)	1
DK (2)	6

Reference Member State (number of products involved in the procedure)	Number of CMSs involved in the procedure
DK (3)	4
DK (3)	7
DK (1)	1
DK (1)	4
DK (1)	1
DK (1)	3
DK (1)	3
DK (1)	4
DK (1)	3
DK (1)	3
DK (1)	5
DK (1)	3
DK (1)	5
DK (2)	9
DK (2)	15
DK (1)	8
DK (1)	1
DK (1)	12
DK (4)	13
DK (1)	1
DK (1)	4
DK (1)	9
DK (1)	1
DK (1)	12
DK (1)	1
DK (1)	1
DK (1)	1
DK (1)	1
DK (2)	3
DK (2)	5
DK (1)	1
DK (1)	1
DK (1)	12
DK (1)	4
DK (2)	7
DK (2)	2
DK (1)	2
DK (1)	1
DK (1)	1
DK (1)	1
DK (1)	3
DK (1)	1
DK (1)	7
DK (2)	8
FI (1)	3
FI (2)	1
FI (6)	7
FI (6)	4
FI (6)	1
FI (2)	1
FI (2)	1
FI (2)	18
FI (2)	1
FI (2)	2
FI (2)	6
FI (2)	3
FI (2)	1
FI (2)	7
FI (2)	6
FI (2)	3
FI (2)	5
FI (2)	1
FI (2)	1

Reference Member State (number of products involved in the procedure)	Number of CMSs involved in the procedure
FI (2)	1
FR (1)	6
FR (1)	4
FR (2)	24
FR (1)	7
FR (1)	7
FR (4)	25
FR (1)	7
NL (1)	1
NL (1)	2
NL (1)	4
NL (3)	11
NL (1)	3
NL (2)	2
NL (1)	1
NL (1)	1
NL (1)	5
SE (1)	10
SE (3)	2
SI (1)	7
UK (3)	2
UK (2)	8
UK (1)	5
UK (1)	7
UK (3)	3
UK (5)	11
UK (1)	11
UK (1)	13
UK (2)	8
UK (1)	1
UK (1)	1
UK (1)	1
UK (1)	1
UK (2)	1
UK (4)	2
UK (1)	7
UK (1)	5
UK (1)	9
UK (4)	10
UK (1)	10

All documents mentioned in this press release can be found at the MRFG website at the European Medicines Authorities Windows under the heading MRFG Guidance.

Information on the above mentioned issues can be obtained from the chair of the MRFG on behalf of the Luxembourg Presidency:

Mrs. Truus Janse-de Hoog
College ter Beoordeling van Geneesmiddelen
Kalvermarkt 53
NL – 2500 Den Haag , The Netherlands

Phone: + 31 70 356 74 08
Fax: + 31 70 356 75 15
e-mail: gm.janse@cbg-meb.nl

From 1st July 2005:

Ms. Shirley Norton
Medicines and Healthcare products Regulatory Agency
1 Nine Elms Lane – Market Towers
London SW8 5NQ
United Kingdom

Phone: + 44 207084 2390
Fax: + 44 207084 2293
e-mail: Shirley.norton@mhra.gsi.gov.uk

*Or you could visit the **MRFG web site** at the EUROPEAN NATIONAL MEDICINES AUTHORITIES WINDOW:*

http://heads.medagencies.org/